Physician profile
Robert M Benson
NPI 1013921428
$5,840.87
in general payments reported to CMS, 2019-2025
41 companies · $905 in 2025
The $905 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $123 · 2021: $452 · 2022: $1,400 · 2023: $1,700 · 2024: $927 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,531.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $846.21 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $800.87 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $572.55 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $560.67 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $314.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.13 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $200.16 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $180.72 | 2019-2022 | |
| Esperion Therapeutics, INC. | $176.57 | 2021-2025 | Nexletol |
| Glaxosmithkline, LLC. | $154.92 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $146.72 | 2020-2023 | Livalo, Seglentis |
| Novartis Pharmaceuticals Corporation | $120.15 | 2021-2023 | |
| Antares Pharma, INC. | $113.75 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Boston Scientific Corporation | $112.01 | 2024-2025 | General - Pain Management |
| Idorsia Pharmaceuticals US INC | $107.03 | 2022-2023 | Quviviq |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.